The 4th Joint Workshop organized by the Chinese Society for Biomaterials (CSBM) and the US Society for Biomaterials (SFB), *the US/China Workshop: Regulation, Standards, and Innovation IV* was successfully held in Minneapolis on April 5th, 2017 during the SFB 2017 Annual Meeting. Following the first three annual workshops hosted in both the US (the 1st at Boston in 2013 and the 2nd at Denver in 2014) and China (the 3rd at Haikou in 2015), it is the first biennial workshop after a joint business meeting between CSBM and US SFB during the 10th World Biomaterials Congress in 2016 determined that future joint workshop will be hosted at each country every other year starting in 2017.

This series of workshop was initially proposed by Professor Xingdong Zhang, past president of the CSBM during a joint business meeting between CSBM and the SFB at the 9th World Biomaterials Congress in June 2012, Chengdu China. Professor Zhang\'s idea was then echoed onsite and strongly supported by the past presidents of the US SFB including professors Joel Bumgardner, Arthur Coury, Lynne Jones, Jeremy Gilbert, Karen Burg, Tony Mikos, Nicholas Peppas and other SFB participants in that meeting.

The goals of this series of workshops are to (1) promote innovation and help to develop biomaterials from concept to commercialized products within and between the two countries; (2) encourage communication and collaboration between US and China in terms of testing, standards, and regulation of biomaterial devices; and (3) discuss potential collaboration in terms of commercialization, business, and clinical research of biomaterials between the two countries. The first three workshops presented a series of talks given by representatives from regulatory agencies (i.e., US FDA and Chinese FDA), government agencies (e.g., US NIST and Chinese Dental Medical Devices Testing Center), global medical device companies (e.g., Medtronic and Lepu Medical Group), and key opinion leaders of biomaterials from both nations (e.g., Professors Xingdong Zhang, Changsheng Liu, Arthur Coury, James M. Anderson, Jack Lemons, Cato Laurencin and Michael Yaszemski).

The 4th joint workshop followed the above tradition as well. The first part of the workshop was composed of presentations given by the invited speakers from regulatory agencies (both CFDA and FDA), companies, and academics. Mrs. Xinli Shi (Director of Evaluation Division III, Center for Medical Device Evaluation (CMDE), CFDA) presented *Special Procedure of Review and Approval for Innovative Medical Devices in China: Requirements and Recent Development*, which introduced the procedures to apply for innovative device evaluation and the current status of such applications. Dr. Edward Margerrison (Director, Office of Science and Engineering, Center for Devices and Radiological Health, US FDA) presented *Collaboration with FDA for Advancing Method Development and Streamlining Product Introductions*. Dr. Margerrison introduced the history, functions and work on regulatory science of the Office of Science and Engineering Laboratory (OSEL) at Center for Devices and Radiological Health, US FDA. Dr. Daozhi Liu (Founder & Partner of Shanghai Sunland Investment Management Co., Ltd.) shared his perspective on "*Cardiovascular Devices Industry and Venture Capital in China*". Mr. Dale Wahlstrom (Co-Founder of the Medical Device Innovation Consortium (MDIC)) discussed the role of a non-profitable organization in government-industry collaborations using the MDIC as a case study. Dr. Hongbing He (Founder and CEO of Shanghai P&P Biotech Co. Ltd.) shared his experience of applying for the innovative medical device with his innovative technologies and products. Dr. SuPing Lyu from Medtronic (Medtronic) presented "Medtronic in China: Innovation and Collaboration". Professor Kai Zhang from Sichuan University introduced the newly launched National Key Research and Development Program of China with a focus on its Key Biomaterials Project. Professor Tom Webster (First Past President of U.S. SFB, Chair of Department of Chemical Engineering, Northeastern University) shared his experience on collaborating with his Chinese partners on developing innovative biomaterial technologies in China. The second part of this workshop is a panel discussion to address the questions from the audience. Speakers further discussed topics including pathways for global companies to apply for innovative medical devices in China and the potential impact on FDA under the administration of new president.

While China is undergoing huge development of biomaterials science and industry with a very fast speed, the US is still the global leader in the field of biomaterials. With a focus on the hot topics on innovation and regulation of biomaterials and related medical devices, this series of workshops has successfully developed a platform to communicate and discuss innovation, standards and regulation of biomaterials for regulatory agencies, standard organizations, industry and academics in both nations.

As a tradition of this series of workshop, US SFB hosted a banquet after the workshop to both honor the birthday of Professor Xingdong Zhang, the current president of the International Union of Societies for Biomaterials Science and Engineering, and celebrate the success of the 4th workshop. The 5th joint workshop will be held in China in 2019 during the China Biomaterials Congress.

The following image shows part of the participants of the US/China Workshop: Regulation, Standards, and Innovation IV, Minneapolis, USA 2017.Image 2

List of participants (from left):

Yufeng Zheng, Yunbing Wang, Len Pinchuck, Daozhi Liu, Hongbing He, Wei Xu, Xinli Shi, Xingdong Zhang, Art Coury, Thomas Webster, Edward Margerrison, Dale Wahlstrom, Liisa Kuhn, Terry Woods, Jack Lemons, Kai Zhang, Wanlu Zhao, Maureen Dreher, Suping Lyu and Hua Ai.
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